Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is included among the 14 Best US Stocks to Buy for Long Term. On December 4, BMO Capital analyst Evan Seigerman boosted the firm’s price target on ...

With T-cell engagers already established as late-line therapies for certain blood cancers, Regeneron has released early data ...

Bispecific antibodies bring multiple tumor-cell-killing mechanisms into play simultaneously. When a T cell is activated and ...

The company's BCMAxCD3 bispecific antibody Lynozyfic (linvoseltamab) got its first FDA approval as a fifth-line or later ...

Regeneron said on Saturday its experimental cancer combination therapy was effective and showed disappearance of the disease ...

Regeneron is adding its name to Tessera Therapeutics’ unique in vivo gene writing program, inking a deal that lets it in on a ...

Morgan Stanley has downgraded Regeneron Pharmaceuticals (REGN) to equal-weight from overweight saying that the stock is ...

If you have ever wondered whether Regeneron Pharmaceuticals is a smart buy at around $718 a share, you are not alone; ...

While shares of Regeneron Pharmaceuticals are climbing this month, investors shouldn't find the stock too pricey, as it's ...

FDA approves Regeneron's Eylea HD for retinal vein occlusion, adding extended dosing options and greater flexibility across multiple eye disease indications.

The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals for the treatment of patients with macular edema following retinal vein ...

The big biotech, which has made genetic medicine a focus in recent years, is paying Tessera $150 million for rights to a ...